Trial Profile
A Double-Blind, Placebo-Controlled, Parallel Group Design Trial of the Selective D3 Antagonist, GSK598809, Added to CBT (Cognitive Behavioral Therapy) and NRT (Nicotine Replacement Therapy) for Smoking Cessation and Prevention of Very Early Relapse to Smoking
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs GSK 598809 (Primary)
- Indications Smoking withdrawal
- Focus Therapeutic Use
- 16 May 2014 New trial record